|
|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to discussing with a patient the risks of certain |
|
controlled substance prescriptions. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. Section 481.0764, Health and Safety Code, is |
|
amended by adding Subsections (f) and (g) to read as follows: |
|
(f) A prescriber, other than a veterinarian, on issuance of |
|
the initial prescription for a Schedule II controlled substance or |
|
an opioid, shall discuss with the patient and, if the patient is a |
|
minor, the patient's parent, conservator, or guardian, or other |
|
person authorized to consent to the minor's medical treatment: |
|
(1) the risk of addiction associated with the drug |
|
prescribed, including any risk of developing a physical or |
|
psychological dependence on the drug; |
|
(2) the risk of overdose associated with the drug |
|
prescribed; and |
|
(3) the danger of taking the drug with |
|
benzodiazepines, alcohol, or other central nervous system |
|
depressants. |
|
(g) A prescriber who discusses the risks of a controlled |
|
substance prescription under Subsection (f) shall note the |
|
discussion in the patient's medical record. |
|
SECTION 2. The change in law made by this Act applies only |
|
to a prescription issued on or after the effective date of this Act. |
|
A prescription issued before the effective date of this Act is |
|
governed by the law in effect on the date the prescription is |
|
issued, and the former law is continued in effect for that purpose. |
|
SECTION 3. This Act takes effect September 1, 2019. |